Recommended Name ?endolysin
Systematic Name ?peptidoglycan amidohydrolase
Alternative Name ?endolysin CD27L
acetylmuramoyl-alanine amidase
acetylmuramyl-alanine amidase
acetylmuramyl-L-alanine amidase
N-acetylmuramic acid L-alanine amidase
N-acetylmuramyl-L-alanine amidase
N-acetylmuramylalanine amidase
N-acylmuramyl-L-alanine amidase
peptidoglycan amidohydrolase
Uniprot IDB6SBV8
General Mode of ActionEnzymatic cleavage of peptidoglycan which results in a rapid lysis of the bacterial cell.
phiBIOTICS Family ?NAM amidase
Reaction ?1. Catalysis of the hydrolysis of the link between N-acetylmuramoyl residues and L-amino acid residues in certain bacterial cell-wall glycopeptides (R04112)
    Corresponding Pfam domain: Amidase_3
    Evidence: experimental (PubMed: 21803993)
Source Organism ?Clostridium phage phiCD27
Target Organism ?Peptoclostridium difficile
Disease ?Clostridium difficile-associated disease
State ?Tested
Reference ?21803993

Studies found: 1

Antimicrobial Agent
Study Type
AdministrationRelevant ResultsAdverse Effects and Other IssuesReference ?
CD27L in vitro
  • set of 30 different Clostridium difficile strains
  • set of Clostridium spp. strains
  • set of major clostridial clusters commonly represented in gastrointestinal tract
  • set of selected commensals
  • set of bacterial strains from different environment
Efficient lytic activity against all 30 C. difficile strains including 2 strains of the hyper virulent ribotype 027.

No lytic activity against any of the other strains tested.
Lysin treatment might cause short-term increase of CDAD symptoms due to lysis-triggered release of internalized toxins. Alhough this issue can be addressed via combined lysin tratment with therapies that neutralize the toxins, more investigation in this field is required.

Other Issues
Lysin was shown to maintain similar levels of activity over a fairly wide range of pHs, between 4.5 and 8.3.